239 related articles for article (PubMed ID: 12696217)
1. Fulvestrant antiestrogen for treatment of breast cancer.
Hancock CM
Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I; Robertson JF
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
[TBL] [Abstract][Full Text] [Related]
3. A new estrogen receptor antagonist--an overview of available data.
Jones SE
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant (Faslodex): current status in the therapy of breast cancer.
Bundred N; Howell A
Expert Rev Anticancer Ther; 2002 Apr; 2(2):151-60. PubMed ID: 12113237
[TBL] [Abstract][Full Text] [Related]
6. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Scott SM; Brown M; Come SE
Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
[TBL] [Abstract][Full Text] [Related]
10. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Abram P; Maass N; Rea D; Simon SD; Steger GG
Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?
Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S1-2. PubMed ID: 16247593
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Chia S; Gradishar W
Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Oakman C; Moretti E; Santarpia L; Di Leo A
Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant in postmenopausal women with advanced breast cancer.
Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
Johnston S
Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S15-8. PubMed ID: 15094760
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant (Faslodex) -- how to make a good drug better.
Robertson JF
Oncologist; 2007 Jul; 12(7):774-84. PubMed ID: 17673609
[TBL] [Abstract][Full Text] [Related]
19. Role of fulvestrant in the management of postmenopausal breast cancer.
Krell J; Januszewski A; Yan K; Palmieri C
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1641-52. PubMed ID: 22050013
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]